{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:48:56Z","timestamp":1792028936419,"version":"4.4.0"},"reference-count":85,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010198","name":"Gobierno de Espa\u00f1a Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","award":["PID2019-104176RB-I00\/AEI\/10.13039\/501100011033"],"award-info":[{"award-number":["PID2019-104176RB-I00\/AEI\/10.13039\/501100011033"]}],"id":[{"id":"10.13039\/501100010198","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007054","name":"Meso Scale Diagnostics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008054","name":"Fundaci\u00f3n Ram\u00f3n Areces","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004837","name":"Ministerio de Ciencia e Innovaci\u00f3n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004837","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Pharmacological Sciences"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.tips.2021.10.004","type":"journal-article","created":{"date-parts":[[2021,11,3]],"date-time":"2021-11-03T18:54:59Z","timestamp":1635965699000},"page":"16-29","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":224,"title":["Update and latest advances in antiretroviral therapy"],"prefix":"10.1016","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1251-6640","authenticated-orcid":false,"given":"Luis","family":"Men\u00e9ndez-Arias","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafael","family":"Delgado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tips.2021.10.004_bb0005","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nm0703-839","article-title":"HIV and AIDS: 20 years of science","volume":"9","author":"Fauci","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.tips.2021.10.004_bb0010","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.ijantimicag.2008.10.010","article-title":"Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV","volume":"33","author":"De Clercq","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.tips.2021.10.004_bb0015","article-title":"Efficacy of initial antiretroviral therapy for HIV-1 infection in adults: a systematic review and meta-analysis of 114 studies with up to 144 weeks' follow-up","volume":"9","author":"Lee","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.tips.2021.10.004_bb0020","first-page":"1204","article-title":"Global burden of 369 diseases and injuries in 204 countries and territories, 1990\u20132019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"396","author":"GBD 2019 Diseases and Injuries Collaborators","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2021.10.004_bb0025","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1007\/s40265-020-01322-y","article-title":"Novel approaches towards a functional cure of HIV\/AIDS","volume":"80","author":"Bailon","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.tips.2021.10.004_bb0030","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/COH.0000000000000535","article-title":"Review: HIV-1 phylogeny during suppressive antiretroviral therapy","volume":"14","author":"Bale","year":"2019","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.tips.2021.10.004_bb0035","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1039\/D0CS01084G","article-title":"Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses","volume":"50","author":"Ma","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.tips.2021.10.004_bb0040","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1021\/acs.jmedchem.7b01337","article-title":"Inhibitors of HIV-1 attachment: the discovery and development of temsavir and its prodrug fostemsavir","volume":"61","author":"Meanwell","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.tips.2021.10.004_bb0045","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1056\/NEJMoa1902493","article-title":"Fostemsavir in adults with multidrug-resistant HIV-1 infection","volume":"382","author":"Kozal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2021.10.004_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/QAI.0b013e3182732746","article-title":"Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope","volume":"62","author":"Pace","year":"2013","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.tips.2021.10.004_bb0055","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.virusres.2016.12.019","article-title":"Viral reverse transcriptases","volume":"234","author":"Men\u00e9ndez-Arias","year":"2017","journal-title":"Virus Res."},{"key":"10.1016\/j.tips.2021.10.004_bb0060","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.sbi.2019.11.011","article-title":"Evolving understanding of HIV-1 reverse transcriptase structure, function, inhibition, and resistance","volume":"61","author":"Xavier Ruiz","year":"2020","journal-title":"Curr. Opin. Struct. Biol."},{"key":"10.1016\/j.tips.2021.10.004_bb0065","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1001\/jama.2020.17025","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2020 recommendations of the International Antiviral Society-USA Panel","volume":"324","author":"Saag","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.tips.2021.10.004_bb0070","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijid.2020.01.035","article-title":"Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: a meta-analysis of randomized controlled trials","volume":"93","author":"Tao","year":"2020","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.tips.2021.10.004_bb0075","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.antiviral.2013.01.007","article-title":"Molecular basis of human immunodeficiency virus type 1 drug resistance: overview and recent developments","volume":"98","author":"Men\u00e9ndez-Arias","year":"2013","journal-title":"Antivir. Res."},{"key":"10.1016\/j.tips.2021.10.004_bb0080","article-title":"Structure and function of retroviral integrase","author":"Maertens","year":"2021","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.tips.2021.10.004_bb0085","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3390\/v13020205","article-title":"Integrase strand transfer inhibitors are effective anti-HIV drugs","volume":"13","author":"Smith","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.tips.2021.10.004_bb0090","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.tips.2020.06.003","article-title":"Structural biology of HIV integrase strand transfer inhibitors","volume":"41","author":"J\u00f3\u017awik","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.tips.2021.10.004_bb0095","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3390\/v13050839","article-title":"HIV protease: historical perspective and current research","volume":"13","author":"Weber","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.tips.2021.10.004_bb0100","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","article-title":"Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase III, randomised controlled non-inferiority trial","volume":"390","author":"Gallant","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2021.10.004_bb0105","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","volume":"390","author":"Sax","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2021.10.004_bb0110","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/hiv.12236","article-title":"Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial","volume":"16","author":"Baxter","year":"2015","journal-title":"HIV Med."},{"key":"10.1016\/j.tips.2021.10.004_bb0115","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1097\/QAD.0000000000002623","article-title":"Tenofovir resistance in early and long-term treated patients on first-line antiretroviral therapy in eight low-income and middle-income countries","volume":"34","author":"Inzaule","year":"2020","journal-title":"AIDS"},{"key":"10.1016\/j.tips.2021.10.004_bb0120","first-page":"111","article-title":"2019 update of the drug resistance mutations in HIV-1","volume":"27","author":"Wensing","year":"2019","journal-title":"Top. Antivir. Med."},{"key":"10.1016\/j.tips.2021.10.004_bb0125","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01216-21","article-title":"Impact of HIV-1 resistance-associated mutations on susceptibility to doravirine: analysis of real-world clinical isolates","author":"Asante-Appiah","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tips.2021.10.004_bb0130","doi-asserted-by":"crossref","first-page":"e549","DOI":"10.1093\/cid\/ciaa259","article-title":"The integrase inhibitors dolutegravir and raltegravir exert proadipogenic and profibrotic effects and induce insulin resistance in human\/simian adipose tissue and human adipocytes","volume":"71","author":"Gorwood","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tips.2021.10.004_bb0135","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1007\/s40265-020-01379-9","article-title":"HIV-1 integrase inhibitors: a comparative review of efficacy and safety","volume":"80","author":"Scarsi","year":"2020","journal-title":"Drugs"},{"key":"10.1016\/j.tips.2021.10.004_bb0140","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1056\/NEJMoa1902824","article-title":"Dolutegravir plus two different prodrugs of tenofovir to treat HIV","volume":"381","author":"Venter","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2021.10.004_bb0145","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s40506-019-00203-7","article-title":"Update on adverse effects of HIV integrase inhibitors","volume":"11","author":"Kolakowska","year":"2019","journal-title":"Curr. Treat. Options Infect. Dis."},{"key":"10.1016\/j.tips.2021.10.004_bb0150","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1093\/jac\/dkv183","article-title":"Efavirenz and the CNS: what we already know and questions that need to be answered","volume":"70","author":"Apostolova","year":"2015","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.tips.2021.10.004_bb0155","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1016\/S2352-3018(19)30080-3","volume":"6","author":"Stellbrink","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.tips.2021.10.004_bb0160","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3018(19)30077-3","article-title":"Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase III, non-inferiority trial","volume":"6","author":"Wohl","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.tips.2021.10.004_bb0165","doi-asserted-by":"crossref","first-page":"e576","DOI":"10.1016\/S2352-3018(19)30149-3","article-title":"Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase III SWORD-1 and SWORD-2 studies","volume":"6","author":"Aboud","year":"2019","journal-title":"Lancet HIV"},{"key":"10.1016\/j.tips.2021.10.004_bb0170","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","volume":"71","author":"van Wyk","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tips.2021.10.004_bb0175","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1093\/jac\/dky299","article-title":"Individual patient data meta-analysis of randomized controlled trials of dual therapy with a boosted PI plus lamivudine for maintenance of virological suppression: GeSIDA study 9717","volume":"73","author":"Perez-Molina","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.tips.2021.10.004_bb0180","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.tips.2021.10.004_bb0185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106220","article-title":"Long-acting drugs and formulations for the treatment and prevention of HIV infection","volume":"57","author":"Flexner","year":"2021","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.tips.2021.10.004_bb0190","doi-asserted-by":"crossref","first-page":"e185","DOI":"10.1016\/S2352-3018(20)30340-4","article-title":"Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase III FLAIR study","volume":"8","author":"Orkin","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.tips.2021.10.004_bb0195","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1056\/NEJMoa1904398","article-title":"Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression","volume":"382","author":"Swindells","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2021.10.004_bb0200","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1097\/QAI.0000000000002466","article-title":"Long-acting injectable cabotegravir + rilpivirine for HIV maintenance therapy: week 48 pooled analysis of phase III ATLAS and FLAIR trials","volume":"85","author":"Rizzardini","year":"2020","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.tips.2021.10.004_bb0205","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1056\/NEJMoa1506110","article-title":"Use of a vaginal ring containing dapivirine for HIV-1 prevention in women","volume":"375","author":"Baeten","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2021.10.004_bb0210","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa1602046","article-title":"Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women","volume":"375","author":"Nel","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2021.10.004_bb0215","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/S2352-3018(20)30304-0","article-title":"Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study","volume":"8","author":"Baeten","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.tips.2021.10.004_bb0220","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1056\/NEJMoa2101016","article-title":"Cabotegravir for HIV prevention in cisgender men and transgender women","volume":"385","author":"Landovitz","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2021.10.004_bb0225","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1038\/s41467-021-23668-x","article-title":"Lipophilic nanocrystal prodrug-release defines the extended pharmacokinetic profiles of a year-long cabotegravir","volume":"12","author":"Gautam","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.tips.2021.10.004_bb0230","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01729-19","article-title":"Translational approach to predicting the efficacy of maraviroc-based regimens as HIV preexposure prophylaxis","volume":"64","author":"Srinivas","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tips.2021.10.004_bb0235","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1056\/NEJMoa2031738","article-title":"Two randomized trials of neutralizing antibodies to prevent HIV-1 acquisition","volume":"384","author":"Corey","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.tips.2021.10.004_bb0240","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.coph.2020.09.017","article-title":"Recent discoveries in HIV-1 reverse transcriptase inhibitors","volume":"54","author":"Gu","year":"2020","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.tips.2021.10.004_bb0245","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104544","article-title":"A HTRF based competitive binding assay for screening specific inhibitors of HIV-1 capsid assembly targeting the C-terminal domain of capsid","volume":"169","author":"Zhang","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.tips.2021.10.004_bb0250","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01058-18","article-title":"Extended-duration MK-8591-eluting implant as a candidate for HIV treatment and prevention","volume":"62","author":"Barrett","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tips.2021.10.004_bb0255","doi-asserted-by":"crossref","first-page":"24533","DOI":"10.1074\/jbc.M114.562694","article-title":"4'-Ethynyl-2-fluoro-2'-deoxyadenosine (EFdA) inhibits HIV-1 reverse transcriptase with multiple mechanisms","volume":"289","author":"Michailidis","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2021.10.004_bb0260","doi-asserted-by":"crossref","first-page":"9274","DOI":"10.1073\/pnas.1605223113","article-title":"Structural basis of HIV inhibition by translocation-defective RT inhibitor 4'-ethynyl-2-fluoro-2'-deoxyadenosine (EFdA)","volume":"113","author":"Salie","year":"2016","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.tips.2021.10.004_bb0265","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1016\/j.chembiol.2018.07.014","article-title":"The high genetic barrier of EFdA\/MK-8591 stems from strong interactions with the active site of drug-resistant HIV-1 reverse transcriptase","volume":"25","author":"Takamatsu","year":"2018","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.tips.2021.10.004_bb0270","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1016\/S2352-3018(19)30372-8","volume":"7","author":"Sch\u00fcrmann","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.tips.2021.10.004_bb0275","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1016\/S2352-3018(21)00021-7","article-title":"Islatravir in combination with doravirine for treatment-naive adults with HIV-1 infection receiving initial treatment with islatravir, doravirine, and lamivudine: a phase IIb, randomised, double-blind, dose-ranging trial","volume":"8","author":"Molina","year":"2021","journal-title":"Lancet HIV"},{"key":"10.1016\/j.tips.2021.10.004_bb0280","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/infdis\/jiz271","article-title":"Once-weekly oral dosing of MK-8591 protects male rhesus macaques from intrarectal challenge with SHIV109CP3","volume":"221","author":"Markowitz","year":"2020","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tips.2021.10.004_bb2005","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1038\/s41591-021-01479-3","article-title":"Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase I trial","volume":"27","author":"Matthews","year":"2021","journal-title":"Nat Med."},{"key":"10.1016\/j.tips.2021.10.004_bb0285","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1126\/science.abb4808","article-title":"Structural and mechanistic bases for a potent HIV-1 capsid inhibitor","volume":"370","author":"Bester","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.tips.2021.10.004_bb0290","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004459","article-title":"Host cofactors and pharmacologic ligands share an essential interface in HIV-1 capsid that is lost upon disassembly","volume":"10","author":"Price","year":"2014","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.tips.2021.10.004_bb0295","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1038\/s41586-020-2443-1","article-title":"Clinical targeting of HIV capsid protein with a long-acting small molecule","volume":"584","author":"Link","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.tips.2021.10.004_bb0300","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1093\/jac\/dkaa060","article-title":"Frequency of capsid substitutions associated with GS-6207 in vitro resistance in HIV-1 from antiretroviral-naive and -experienced patients","volume":"75","author":"Marcelin","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.tips.2021.10.004_bb2010","series-title":"Lenacapavir resistance analysis in a phase Ib clinical proof-of-concept study","author":"Margot","year":"2020"},{"key":"10.1016\/j.tips.2021.10.004_bb0305","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02057-20","article-title":"Absence of lenacapavir (GS-6207) phenotypic resistance in HIV Gag cleavage site mutants and in isolates with resistance to existing drug classes","volume":"65","author":"Margot","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tips.2021.10.004_bb2015","series-title":"GS-6207 sustained delivery formulation supports 6-month dosing interval","author":"Begley","year":"2020"},{"key":"10.1016\/j.tips.2021.10.004_bb2020","series-title":"Long-acting HIV capsid inhibitor effective as prep in a SHIV rhesus macaque model","author":"Bekerman","year":"2021"},{"key":"10.1016\/j.tips.2021.10.004_bb0310","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3390\/v12090940","article-title":"HIV-1 maturation: lessons learned from inhibitors","volume":"12","author":"Kleinpeter","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.tips.2021.10.004_bb0315","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02173-20","article-title":"A phase I evaluation of the pharmacokinetics and tolerability of the HIV-1 maturation inhibitor GSK3640254 and tenofovir alafenamide\/emtricitabine in healthy participants","volume":"65","author":"Pene Dumitrescu","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tips.2021.10.004_bb0320","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1093\/infdis\/jiaa377","article-title":"Clinical trials of broadly neutralizing monoclonal antibodies for human immunodeficiency virus prevention: a review","volume":"223","author":"Mahomed","year":"2021","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.tips.2021.10.004_bb0325","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1128\/AAC.01215-07","article-title":"Design and profiling of GS-9148, a novel nucleotide analog active against nucleoside-resistant variants of human immunodeficiency virus type 1, and its orally bioavailable phosphonoamidate prodrug, GS-9131","volume":"52","author":"Cihlar","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tips.2021.10.004_bb0330","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/17425255.2019.1673367","article-title":"Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment","volume":"15","author":"Wang","year":"2019","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.tips.2021.10.004_bb0335","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02635-18","article-title":"Halogen bond interactions of novel HIV-1 protease inhibitors (PI) (GRL-001-15 and GRL-003-15) with the flap of protease are critical for their potent activity against wild-type HIV-1 and multi-PI-resistant variants","volume":"63","author":"Hattori","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.tips.2021.10.004_bb0340","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1093\/cid\/ciy652","article-title":"Phase I pharmacokinetic trial of 2 intravaginal rings containing different dose strengths of vicriviroc (MK-4176) and MK-2048","volume":"68","author":"Liu","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tips.2021.10.004_bb0345","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/cid\/ciy653","article-title":"Phase I safety and pharmacokinetics study of MK-2048\/vicriviroc (MK-4176)\/MK-2048A intravaginal rings","volume":"68","author":"Hoesley","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.tips.2021.10.004_bb0350","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbc.2021.100363","article-title":"Optimized binding of substituted quinoline ALLINIs within the HIV-1 integrase oligomer","volume":"296","author":"Sun","year":"2021","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2021.10.004_bb0355","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.str.2020.12.001","article-title":"Allosteric HIV integrase inhibitors promote formation of inactive branched polymers via homomeric carboxy-terminal domain interactions","volume":"29","author":"Gupta","year":"2021","journal-title":"Structure"},{"key":"10.1016\/j.tips.2021.10.004_bb0360","doi-asserted-by":"crossref","first-page":"735","DOI":"10.3390\/v13050735","article-title":"HIV-1 entry and membrane fusion inhibitors","volume":"13","author":"Xiao","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.tips.2021.10.004_bb0365","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2019.104613","article-title":"Ribonuclease H, an unexploited target for antiviral intervention against HIV and hepatitis B virus","volume":"171","author":"Tramontano","year":"2019","journal-title":"Antivir. Res."},{"key":"10.1016\/j.tips.2021.10.004_bb0370","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.drudis.2018.01.022","article-title":"NCp7: targeting a multitask protein for next-generation anti-HIV drug development part 2. Noncovalent inhibitors and nucleic acid binders","volume":"23","author":"Iraci","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.tips.2021.10.004_bb0375","first-page":"221","article-title":"Research progress of HIV-1 Nef inhibitors","volume":"22","author":"Lv","year":"2020","journal-title":"AIDS Rev."},{"key":"10.1016\/j.tips.2021.10.004_bb0380","doi-asserted-by":"crossref","first-page":"14592","DOI":"10.1074\/jbc.RA120.013404","article-title":"A novel HIV-1 inhibitor that blocks viral replication and rescues APOBEC3s by interrupting vif\/CBF\u03b2 interaction","volume":"295","author":"Duan","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.tips.2021.10.004_bb0385","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.cell.2020.03.005","article-title":"Curing HIV: seeking to target and clear persistent infection","volume":"181","author":"Margolis","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.tips.2021.10.004_bb0390","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1146\/annurev-med-052716-031710","article-title":"Novel latency reversal agents for HIV-1 cure","volume":"69","author":"Spivak","year":"2018","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.tips.2021.10.004_bb0395","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/COH.0000000000000467","article-title":"4'-Ethynyl-2-fluoro-2'-deoxyadenosine, MK-8591: a novel HIV-1 reverse transcriptase translocation inhibitor","volume":"13","author":"Markowitz","year":"2018","journal-title":"Curr. Opin. HIV AIDS"},{"key":"10.1016\/j.tips.2021.10.004_bb0405","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113380","article-title":"An insight on medicinal aspects of novel HIV-1 capsid protein inhibitors","volume":"217","author":"Sun","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.tips.2021.10.004_bb0410","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01039-21","article-title":"A small molecule, ACAi-028, with anti-HIV-1 activity targets a novel hydrophobic pocket on HIV-1 capsid","volume":"65","author":"Chia","year":"2021","journal-title":"Antimicrob. Agents Chemother."}],"container-title":["Trends in Pharmacological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614721001930?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165614721001930?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T09:12:39Z","timestamp":1759050759000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165614721001930"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":85,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0165614721001930"],"URL":"https:\/\/doi.org\/10.1016\/j.tips.2021.10.004","relation":{},"ISSN":["0165-6147"],"issn-type":[{"value":"0165-6147","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Update and latest advances in antiretroviral therapy","name":"articletitle","label":"Article Title"},{"value":"Trends in Pharmacological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tips.2021.10.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}